drugset
drugset / Trial / NCT05432713

A Study of LP-168 in Healthy Volunteers

NCT05432713 ↗

Phase 1 Completed 70 enrolled Guangzhou Lupeng Pharmaceutical Company LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase I study designed to assess the safety, tolerability and pharmacokinetics of LP-168 in healthy human volunteers.

Timeline

Start
2022-05-14
Primary completion
2022-11-20
Completion
2022-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Rocbrutinib Small molecule — Oral

Indications

multiple sclerosis neuromyelitis optica